Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-alfa Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A10223892" target="_blank" >RIV/61989592:15110/11:10223892 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1371/journal.pone.0023022" target="_blank" >http://dx.doi.org/10.1371/journal.pone.0023022</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0023022" target="_blank" >10.1371/journal.pone.0023022</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-alfa Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile

Popis výsledku v původním jazyce

Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-a) was the treatment of choice in chronic myeloid leukemia (CML). Curiously, some IFN-a treated patients were able to discontinue therapy without disease progression. The aim of this project was to study the immunomodulatory effects of IFN-a in CML patients in prolonged remission and isolate biological markers predicting response. Due to rarity of patients on IFN-a monotherapy, a relatively small cohort of patients still on treatment (IFN-ON, n = 10, median therapy duration 11.8 years) or had discontinued IFN-a therapy but remained in remission for .2 years (IFN-OFF, n = 9) were studied.

Název v anglickém jazyce

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-alfa Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile

Popis výsledku anglicky

Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-a) was the treatment of choice in chronic myeloid leukemia (CML). Curiously, some IFN-a treated patients were able to discontinue therapy without disease progression. The aim of this project was to study the immunomodulatory effects of IFN-a in CML patients in prolonged remission and isolate biological markers predicting response. Due to rarity of patients on IFN-a monotherapy, a relatively small cohort of patients still on treatment (IFN-ON, n = 10, median therapy duration 11.8 years) or had discontinued IFN-a therapy but remained in remission for .2 years (IFN-OFF, n = 9) were studied.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PLoS One

ISSN

1932-6203

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

"e23022"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—